Biotheranostics, a subsidiary of Hologic, is a leading provider of proprietary genomic assays for personalized disease management in oncology, offering tests such as Breast Cancer Index and CancerTYPE ID. Their genomic tests are recognized by ASCO and NCCN Clinical Practice Guidelines, providing valuable insights for predicting the benefit of extended endocrine therapy in HR-positive, early-stage breast cancer and identifying tumor type and subtype for metastatic cancer patients with unknown or unclear diagnoses.
With a commitment to precision medicine, Biotheranostics continues to deliver innovative genomic solutions that aid in personalized treatment decisions, contributing to improved patient outcomes in the field of oncology.
Generated from the website